Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study.
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Kathleen N. Moore, Dhanusha Sabanathan, Yiqun Du, Huaxin Duan, Xiumin Li, Feng Wang, Omkar Marathe, Hua Yang, Vicky Makker, Whitfield Growdon, Jim Coward, Peng Zhao, Liming Liu, Rong Shi, Shengxue Liu, Wei Gu, Yang Qiu, Zhongyuan Zhu, Jian Zhang, Erika P. Hamilton
Institutions: OU Health Stephenson Cancer Center, University of Oklahoma, Macquarie University, Fudan University Shanghai Cancer Center, Hunan Provincial People's Hospital, First Affiliated Hospital of Zhengzhou University, Affiliated Hospital of Hebei University, Memorial Sloan Kettering Cancer Center, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Icon (Australia), First Affiliated Hospital Zhejiang University, Duality Biotherapeutics, Inc. (China), Shanghai Medical College of Fudan University, Fudan University, Sarah Cannon, Tennessee Oncology
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4379282945